Abstract：Objective To analyze the feasibility of Guizhi Fuling Capsules in the treatment of uterine leiomyoma in perimenopausal period.Methods 387 cases of women with uterine leiomyoma in perimenopausal period treated in our hospital from January 2015 to January 2016 were randomly divided into observation group(200 cases)and control group (187 cases)according to treatment methods.Patients in the control group were treated with oral Mifepristone Tablets, 12.5 mg once,qd;patients in the observation group were given Guizhi Fuling Capsule based on the control group,4 capsules each time,tid,all patients were treated for 6 months.The therapeutic effects were compared between the two groups after treatment;the levels of estradiol(E2),hormones(P),luteinizing hormone(LH),follicle stimulating hormone(FSH)and the volume of uterine leiomyoma were measured and compared before and after treatment.Results The total effective rate of the observation group and the control group was 96.00%and 75.40%,the difference between the two groups was statistically significant(P＜0.05).After treatment,the serum levels of E2,P,LH and FSH in the two groups were significantly lower than those before treatment,and the levels of the observation group were significantly lower than those of the control group,the differences were statistically significant(P＜0.05);the volume of uterine fibroids of the two groups was significantly less than that before treatment,and the volume of uterine leiomyoma in the observation group was significantly less than that in the control group,the differences were statistically significant(P＜0.05).Conclusion Mifepristone combined with Guizhi Fuling Capsules can effectively improve the curative effect of patients with uterine leiomyoma in perimenopausal period,suitable for clinical promotion.
Holdsworth-Carson SJ，Zaitseva M，Vollenhoven BJ，et al. Clonality of smooth muscle and fibroblast cell populations isolated from human fibroid and myometrial tissues[J].Mol Hum Reprod，2014，20（3）：250-259.
Hausknecht RU.Comment：analysis of severe adverse events related to the use of mifepristone as an abortifacient[J].Ann Pharmacother，2006，40（4）：1217-1220.
Fleseriu M，Findling JW，Koch CA，et al.Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone[J].J Clin Endocrinol Metab，2014，99（10）：3718-3727.
京公网安备 11010502046607号